

Coördinatiecommissie Antibioticabeleid / Commission de coordination de la politique antibiotique

Evidence-Based Guidelines for the Hospital Use of Antibiotics

BACTERIAL MENINGITIS Adults & Children

First draft


Bénédicte Delaere

Dirk Ramaekers

Introduction

The views in this draft are not intended to be implemented in clinical practice at this stage !

Evaluation of the literature



Criteria for considering studies

Inclusion criteria: clinical signs suggestive of BM on admission and bacteriological documentation (Gramstain, antigen, culture)

Exclusion criteria: no description of the population and of the end-points.
 (mortality, sequelae, safety).
 History of neurological abnormalities.
 Studies with less than 20 patients.

AB treatment in childhood BM

* 20 RCTs evaluated, 2 excluded (1960-2000) Few children under 1 month of age 10/20 with acceptable methodology *** 3 major pathogens evaluated:** H. influenzae b > N. meningitidis > S. pneumoniae Type 2 error: sub-analysis by pathogen Most studies < 100 evaluable patients No study with resistant strains of S. pneumoniae 畿 or with L. monocytogenes

AB treatment in children BM

- * 3rd G cephalos' vs pen or ampi + CHL (9). Same efficacy: trend towards earlier sterilization, fewer neurological sequelae. CHL alone: less effective.
- ★ Cefurox vs ampi + CHL or ceftriax (2): same efficacy, trend towards a delay of sterilization / ✓ hearing loss.
- No difference between 3rd G cephalos' agents (1) nor between 3rd G-4rd G cephalos' (1), excepted for biliary pseudo-lithiasis (ceftriaxone)
- No difference between 3rd G cephalos' and meropenem
 (2)
- **Ceftazidime vs ampi + CHL: same efficacy**

(19 S. pneumoniae / 90)

AB treatment in children BM

Duration of treatment (case-series)
Standard (16): N. meningitidis 7 d
H. influenzae 7-10 d
S. pneumoniae 10-14 d
Short course (2) : 4d, 6d, 7d vs 8d,12d,14d
As effective (rapid recovery) but few patients by pathogen

Dosage: no dose-ranging studies comparing different dosage of the same AB (case--series)

Steroid therapy in children BM

*** 5 meta-analysis, 1 more thorough** (1997) 11 RCTs, 848 patients: 522 Hib, 122 S. pneu, 125 N. men Dexamethasone 4d 0,6 mg/kd/d, only 4 RCTs with the same timing of administration. Decrease of hearing loss in Hib BM. Trend towards decrease of severe hearing loss in S. pneu (Significant if early administration but vulnerable to exclusion of 1 study...) > No efficacy on other neurological disorders. *** 2 RCTs >1996:** trend towards higher mortality (1), 2d vs 4d similar (n=113, only 11 S. pneumo)

AB treatment in adult BM

 * 7 RCTs included, 1 excluded
 * No studies with acceptable methodology Meropenem vs 3rd G cephalos' (1) Ceftriaxone vs ampi + CHL (4) Cefuroxime vs ampi + CHL (1) Ceftriaxone vs penicillin (*N. meningitidis*, 1)
 * No comparison of duration of treatment and

of dosages

* Case reports on L. monocytogenes BM

Steroid therapy in adult BM

No meta-analysis available
 2 RCTs with unacceptable methodology

Lack of evidence of any advantage

Global microbiological data

* Pathogen distribution:

 <u>< 3 months:</u> Group B strepto, L. monocytogenes, E. coli and S. pneumoniae.
 <u>Children</u>: S. pneumoniae, N. meningitidis and H. influenzae
 <u>Adults</u>: S. pneumoniae, N. meningitidis and <u>H. influenzae + L. monocytogenes</u>

(> 50y)

Global microbiological data

Dramatic decrease of Hib BM since vaccination S. pneumoniae & N. meningitidis \rightarrow \triangle age distribution (mean 20 years) Emergence of S. pneumoniae resistant to penicillin → variability according to:

- countries / geographic areas

- primary infection sites

Belgian microbiological data (2000)

* N. meningitidis > S. pneumoniae >> Hib N. meningitidis: incidence 2,6/10⁵, ≯ type C **94.4% MIC penicillin < 0,064 μg/ml** No resistance to 3rd G cephalos' * S. pneumoniae: 51 strains (CSF) (45% < 5 y, 33% > 50y) Serotypes 6,14,9,19 21,5% resistant to penicillin (HLR: 0) 7,8% resistant to 3rd G cephalos' (HLR:1) In 1999, 4 reported cases of Hib BM

Treatment of resistant S. pneumo

- Case-reports, case-series, animal studies
 Vancomycin + 3rd G Cephalos'! Steroids (adults) + rifampin ?
- Meropenem: in vitro efficacy, case-reports of treatment failure
- 3rd G Cephalos' HD (intermediate strains 0,5 μg/ml<MIC< 1) 300 mg/kg/ d max. 24g/d but reports on failure
- Routine control spinal tap after 48h of AB (particularly if poor evolution)

Management	Antibiotic therapy	Level of evidence
Empiric therapy	cefotax or ceftriax (> 1 month)	1b
	Children < 3 months and adults > 50y (or suggestive presentation) : + ampi	3

	Antibiotic therapy	Level of evidence
Documented	<i>N. meningitidis</i> : peni or ampi or 3 rd GC.	1b
therapy	Duration: 7d (or 5d if rapid recovery and 3 rd GC).	3
	S. pneumoniae: wait the MIC peni and 3 rd	4
	GC: Peni S: Peni or ampi	1b
	Peni R-3 rd GC S: 3 rd GC	3
	Peni R-3 rd GC I-R: vanco + 3 rd GC	3
	(or meropenem ?) (3 rd GC I: high dose cefotax?)	
	Duration: 10-14d (7d if rapid recovery and 3 rd GC)	3

	Antibiotic therapy	Level of evidence
Documented therapy	<i>H. influenzae:</i> 3 rd GC or ampi (if S). Duration: 7-10 d	1b 3
	S. agalactiae: peni (15-21d) + genta (3d)	3
	E. coli: 3 rd GC, 21d	3
	L. monoc : ampi 15-21d + genta	3

Dosage (Level 3) <u>Children</u>

Peni 250.000 UI/kg/d (div 6) Ampi 200 mg/kg/d (div 4) Cefotax 200-300 mg/kg/d (div 4) Ceftriax 80-100 mg/kg/d (div 1-2) Genta 7,5 mg/kg/d (div 3)

<u>Adults</u>

24 MIU/d (div 6) 12g/d (div 6) 12 (18-24)g/d (div 6) 4g/d (div 2) 5 mg/kg/d (div 3)

Evidence: Steroid therapy

Adults: no evidence of benefit
 Children:

 Not vaccinated Hib or unknown: dexa 0,6 mg/kg/d (div 4) for 2 d.

 If dexa is administered in a other situation (no HL evidence of benefit): before or concomitant to AB and for 4d.





Antibiotic prophylaxis (secondary case)

Clinical management Timing of the AB and LP Timing and indication of cerebral CT Viral meningitis

GDG Bacterial Meningitis

- * Neurology:
- * Pediatrics:

- Intensive care:
- Infectiology:
- Microbiology:

- M. Van Zandijcke, Sint Jan Brugge
 C. Sindic, Saint-Luc Bruxelles
 S. Van Lierde, Tienen
 J. Levy, Saint-Pierre, Bruxelles
 L. Maieux, Antwerp
 T. Dujernier, Saint-Pierre Ottignies
- W. Peetermans, Gasthuisberg Leuven
 JP. Thys, Erasme Bruxelles
 J. Verhaegen, Gasthuisberg Leuven
 P. Demol, CHU Liège



www.health.fgov.be/antibiotics



In meningitis due to *N. meningitidis*, a third generation cephalosporin may be administered during <u>the all course</u> of treatment.






A short course of AB therapy (cephalos) is appropriate in case of rapid recovery





High dose of cefotaxime is appropriate in the treatment of intermediate strains of *S. pneumoniae* (Peni R, cephalo I)






Ampicillin has to be added to a third generation cephalosporin in adult older than 50 years old.





Dexamethasone has to be administered even if children are vaccinated against type b *H. influenzae*





Dexamethasone should be included in the treatment of adult BM

